The Supreme Court has directed the Central Government to constitute a committee to address unethical promotional practices in the pharmaceutical industry. The Court held that a regulatory framework must be judged not by its existence on paper but by its efficacy and actual enforcement. Framing the issue as a fundamental rights matter, the bench linked unethical pharma marketing directly to the right to health under Article 21, placing an obligation on the State to ensure meaningful regulation.

This ruling sits at the intersection of Article 21 (right to life and personal liberty) and the State's positive obligation to regulate private actors whose conduct threatens public health. The Supreme Court has progressively expanded Article 21 since Maneka Gandhi v. Union of India (1978) to include the right to health, confirmed explicitly in Paschim Banga Khet Mazdoor Samity (1996) and Consumer Education and Research Centre v. Union of India (1995). The Court's direction here does two legally significant things. First, it articulates the 'efficacy and enforcement' test: a regulatory framework is constitutionally insufficient if it exists only formally without real enforcement machinery. This mirrors the proportionality and reasonableness standards the Court applies when judging State action under Articles 14 and 21. Second, it creates a positive State duty — not merely a negative restraint — to actively police private pharmaceutical companies whose marketing practices compromise informed medical decision-making and patient safety. The Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which has been voluntary since 2015, is the direct policy background. The Court's skepticism of self-regulation reflects the broader constitutional principle that voluntary codes without statutory teeth cannot satisfy the State's Article 21 obligations. For CLAT PG, the key doctrinal move is that the Court is applying the 'procedure established by law must be fair, just, and reasonable' standard (post-Maneka Gandhi) to evaluate whether the regulatory architecture itself is constitutionally adequate — not just whether a specific law was followed.